Project

A phase 3, multicenter, open-label, randomized, study of gilteritinib versus midostaurin in combination with induction and consolidation therapy followed by oneyear mainte-nance in patients with newly diagnosed Acute Myeloid Leu-kemia (AML) or Myelodysplastic syndromes with excess blasts-2 (MDS-EB2) with FLT3 mutations eligible for intensive chemotherapy

Ongoing - recruitment closed · 2021 until 2028

Schittenhelm Marcus, Kehl Jeanine, Quinter Janine